Circulating GDF15 levels reflect metabolic and inflammatory burden in early dysglycemia: findings from the ADIOS cohort
Authors' conclusion
Circulating levels of GDF15 measured at diagnosis reflect the burden of adverse metabolic and inflammatory traits in individuals with early dysglycemia
Study context
- Population
- Treatment-naive adults with normal glucose tolerance (NGT), prediabetes or newly diagnosed T2D; Anam Diabetes Observational Study
- Participants
- 281 adults
- Exposure
- Highest vs lower GDF15 tertiles
- Outcome
- Associations between GDF15 levels and predefined metabolic abnormalities
- Follow-up
- At diagnosis (baseline)
Methodological detailsprospective cohort (ADIOS)
- Prospective cohort (ADIOS)
Main finding
As reported in the abstract
Predefined metabolic abnormalities in early dysglycemia
Each group vs NGTEstimate (95% CI)
Highest GDF15 tertile
aOR, central obesity 2.59(1.19–5.63)
Highest GDF15 tertile
aOR, elevated HOMA2-IR 4.12(1.70–9.99)
Highest GDF15 tertile
aOR, elevated high-sensitivity C-reactive protein 2.69(1.22–5.92)
Highest GDF15 tertile
aOR, elevated fatty liver index 2.75(1.22–6.18)
Observational data: associations, not effects.
Further findings
GDF15 levels across glycemic status
- Circulating GDF15 increased progressively from NGT to prediabetes and newly diagnosed T2D
Original publication
Circulating GDF15 levels reflect metabolic and inflammatory burden in early dysglycemia: findings from the ADIOS cohort. Diabetes Res Clin Pract. Published 27 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →